Hemispherx Biopharma, Inc.

Company Listings from SPi: Hemispherx Biopharma, Inc.

You are here: Home >> SPi Company Listings >> Hemispherx Biopharma, Inc.

 

Hemispherx Biopharma, Inc.

Website:
http://

Search for other references to "hemispherx" on SPi News

Latest Hemispherx Biopharma, Inc. News

Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center OCALA, Fla., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medic...... 17:50 GMT Tuesday 8th January 2019

Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome OCALA, Fla., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medic...... 13:30 GMT Wednesday 2nd January 2019

Hemispherx Biopharma Issues Business Update to Clarify Apple iOS12 Stocks Application ‘No Recent Stories’ Misinformation OCALA, Fla., Dec. 26, 2018 (GLOBE NEWSWIRE) -- continues to work with Apple and other affected parties for a solution to correct Apple iOS12 Stocks Application misinformation and...... 13:30 GMT Wednesday 26th December 2018

Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program OCALA, Fla., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medic...... 13:30 GMT Wednesday 19th December 2018

Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States OCALA, Fla., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medic...... 13:30 GMT Monday 17th December 2018

Hemispherx Biopharma Issues Letter to Stockholders OCALA, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business u...... 13:30 GMT Wednesday 12th December 2018

Hemispherx Reports 2018 Third Quarter and First Nine Months Financial Results OCALA, Fla., Nov. 15, 2018 (GLOBE NEWSWIRE) -- announces financial results for the three and nine months ended September 30, 2018, and provides a business update.Highlights of th...... 14:04 GMT Thursday 15th November 2018

Hemispherx’s Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed OCALA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medic...... 22:39 GMT Monday 29th October 2018

Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference ORLANDO, Fla., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet med...... 13:30 GMT Wednesday 24th October 2018

Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders ORLANDO, Fla., Oct. 22, 2018 (GLOBE NEWSWIRE) -- announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business...... 13:30 GMT Monday 22nd October 2018

Buy Hemispherx Biopharma, Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us